Crossmark

Efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in nasopharyngeal carcinoma in vitro and in vivo

Published Online: 2018-05-03

Published Print: 2018-12

Authors

Huang, Yan

Tian, Ying

Zhao, Yuanyuan

Xue, Cong

Zhan, Jianhua

Liu, Lin

He, Xiaobo

Zhang, Li
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81502355, 81502352)
License Information

Version of Record valid from 2018-05-03
More Information

Publication History

Received: 2017-09-04

Accepted: 2018-01-22

Published: 2018-05-03

Document is current